NCT01729806 is a Phase 1 clinical trial of Ipilimumab in CD20 Positive, sponsored by National Cancer Institute (NCI).

Who is sponsoring NCT01729806?

NCT01729806 is sponsored by National Cancer Institute (NCI).

What drugs are being tested in NCT01729806?

Interventions in NCT01729806: Ipilimumab, Laboratory Biomarker Analysis, Rituximab.

What condition does NCT01729806 study?

NCT01729806 studies CD20 Positive, Recurrent B-Cell Non-Hodgkin Lymphoma, Refractory B-Cell Non-Hodgkin Lymphoma.

Is NCT01729806 still recruiting?

NCT01729806 is currently completed. Last updated 11 April 2018.

Last reviewed 2018-04-11 · How we verify

NCT01729806

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Ipilimumab and Rituximab in Treating Patients With Relapsed or Refractory B-cell Lymphoma

Completed Phase 1 Last updated 11 April 2018

What this trial tests

Phase 1 trial testing Ipilimumab in CD20 Positive in 32 participants. Completed in 30 March 2018.

Timeline

19 November 2012

Primary endpoint
30 March 2018

30 March 2018

Quick facts

Lead sponsor	National Cancer Institute (NCI)
Phase	Phase 1
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	32
Start date	19 November 2012
Primary completion	30 March 2018
Estimated completion	30 March 2018
Sites	7 locations across United States

Drugs / interventions tested

Ipilimumab — full drug profile →
Laboratory Biomarker Analysis — full drug profile →
Rituximab — full drug profile →

Conditions studied

CD20 Positive — all drugs for CD20 Positive →
Recurrent B-Cell Non-Hodgkin Lymphoma — all drugs for Recurrent B-Cell Non-Hodgkin Lymphoma →
Refractory B-Cell Non-Hodgkin Lymphoma — all drugs for Refractory B-Cell Non-Hodgkin Lymphoma →

Sponsor

National Cancer Institute (NCI)

Who can join

18 and older, any sex, with CD20 Positive or Recurrent B-Cell Non-Hodgkin Lymphoma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This partially randomized phase I trial studies the side effects and best dose of ipilimumab when given together with rituximab in treating patients with B-cell lymphoma that has returned or has not responded to treatment. Monoclonal antibodies, such as ipilimumab and rituximab, may interfere with the ability of cancer cells to grow and spread.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

At the bedside: CTLA-4- and PD-1-blocking antibodies in cancer immunotherapy.
Callahan MK, Wolchok JD. · · 2013 · cited 246× · PMID 23667165 · DOI 10.1189/jlb.1212631
Regulatory T cells in immune checkpoint blockade antitumor therapy.
Zhang A, Fan T, Liu Y, Yu G, et al · · 2024 · cited 94× · PMID 39516941 · DOI 10.1186/s12943-024-02156-y
Checkpoint inhibitors in hematological malignancies.
Ok CY, Young KH. · · 2017 · cited 93× · PMID 28482851 · DOI 10.1186/s13045-017-0474-3
Trial Watch: Immunostimulatory monoclonal antibodies in cancer therapy.
Aranda F, Vacchelli E, Eggermont A, Galon J, et al · · 2014 · cited 92× · PMID 24701370 · DOI 10.4161/onci.27297
Immune checkpoint blockade in cancer treatment: a double-edged sword cross-targeting the host as an "innocent bystander".
Gelao L, Criscitiello C, Esposito A, Goldhirsch A, et al · · 2014 · cited 56× · PMID 24594636 · DOI 10.3390/toxins6030914
Checkpoint Inhibitors and Other Immune Therapies for Hodgkin and Non-Hodgkin Lymphoma.
Matsuki E, Younes A. · · 2016 · cited 40× · PMID 27193488 · DOI 10.1007/s11864-016-0401-9
Monoclonal Antibody Therapies for Hematological Malignancies: Not Just Lineage-Specific Targets.
Cuesta-Mateos C, Alcaraz-Serna A, Somovilla-Crespo B, Muñoz-Calleja C. · · 2017 · cited 39× · PMID 29387053 · DOI 10.3389/fimmu.2017.01936
Immune-Checkpoint Inhibitors in B-Cell Lymphoma.
Armengol M, Santos JC, Fernández-Serrano M, Profitós-Pelejà N, et al · · 2021 · cited 38× · PMID 33430146 · DOI 10.3390/cancers13020214

Verify or expand the search:

Other trials of Ipilimumab

Trials testing the same drug.

NCT07444619 — A Phase I Study of Pazopanib in Combination With Trabectedin, Ipilimumab and Nivolumab (TraPIN) in Pediatric and Young A · Phase 1 · not yet recruiting
NCT07383441 — Adding Biotherapy or Placebo to Standard Treatment for Advanced Kidney Cancer · Phase 3 · not yet recruiting
NCT07510334 — VSV-IFNβ-NIS With Ipilimumab and Nivolumab for the Treatment of Advanced or Metastatic Clear Cell Renal Cell Carcinoma · Phase 2 · not yet recruiting
NCT07293351 — A Study to Evaluate the Safety, Tolerability, and Efficacy of Pumitamig Alone or in Combination With Ipilimumab or Caboz · Phase 1, PHASE2 · recruiting
NCT07128680 — Immunotherapy (Nivolumab and Ipilimumab) With and Without a Live Biotherapeutic Product (EXL01) for the Treatment of Met · Phase 1 · recruiting

Other recruiting trials for CD20 Positive

Currently open trials in the same condition.

NCT04007029 — Modified Immune Cells (CD19/CD20 CAR-T Cells) in Treating Patients With Recurrent or Refractory B-Cell Lymphoma or Chron · Phase 1 · active not recruiting
NCT03946878 — Venetoclax and Acalabrutinib in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma · Phase 2 · active not recruiting
NCT01959698 — Carfilzomib, Rituximab, Ifosfamide, Carboplatin, and Etoposide in Treating Patients With Relapsed or Refractory Stage I- · Phase 1 · active not recruiting
NCT01880567 — Ibrutinib and Rituximab in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma or Older Patients With New · Phase 2 · active not recruiting

Other National Cancer Institute (NCI) trials

Trials by the same sponsor.

NCT07147231 — Testing the Effectiveness of the Anti-cancer Drug Pidnarulex (CX-5461), in Combination With Another Anti-cancer Drug Cem · Phase 1, PHASE2 · recruiting
NCT07572123 — Evaluating the Addition of Maintenance Immunotherapy Compared to the Usual Treatment of Chemotherapy and Autologous Stem · Phase 2, PHASE3 · not yet recruiting
NCT07281417 — Testing the Addition of Cemiplimab (REGN2810) to Chemotherapy Treatment Given Prior to Surgery in Patients With Sinonasa · Phase 2 · recruiting
NCT07012044 — A Study to Find the Highest Dose of Cedazuridine and Decitabine Combination With Filgrastim as a Treatment Option After · Phase 1 · not yet recruiting
NCT07437950 — Comparing Different Treatment Lengths for Venetoclax in Older People With Newly Diagnosed Acute Myeloid Leukemia (A Myel · Phase 2 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT01729806 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by National Cancer Institute (NCI)
Last refreshed: 11 April 2018

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT01729806.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing